Larimar Therapeutics (LRMR) Projected to Release Earnings on Thursday

Larimar Therapeutics (NASDAQ:LRMR) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 9:30 AM ET.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.08. On average, analysts expect Larimar Therapeutics to post ($1.37) EPS for the current fiscal year and ($1.32) EPS for the next fiscal year.

Larimar Therapeutics Stock Up 7.2%

NASDAQ:LRMR opened at $2.54 on Wednesday. Larimar Therapeutics has a 52-week low of $1.91 and a 52-week high of $6.42. The firm has a market cap of $263.86 million, a P/E ratio of -1.30 and a beta of 0.73. The business’s 50-day moving average price is $3.15 and its 200 day moving average price is $3.79.

Analyst Ratings Changes

Several analysts have issued reports on the company. Leerink Partners started coverage on Larimar Therapeutics in a report on Monday, September 14th. They set an “outperform” rating and a $13.00 price objective on the stock. Wedbush lowered their target price on Larimar Therapeutics from $12.00 to $11.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $10.33.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases.